Skip to content

Debatforum

20.6k Emner 126.8k Indlæg

Aktie- og finansdebat

  • CHEMOMETEC: ØU hæver kursmålet til 350 DKK

    2
    0 Votes
    2 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    "ChemoMetec - Ny CEO godt fra land, stærkt 2020 i kortene Vi har haft lejlighed til at møde ChemoMetecs nye CEO til en snak om selskabet, fremtiden og det netop aflagte halvårsregnskab. Vi føler os forstærket i grundsynet af et højprofitabelt, markedsledende selskab med stærke produkter og vækstudsigter. Samtidigt hørte vi intet, som tyder på, at den tidligere så fremgangsrige opskrift er ved at blive ændret. Vi vælger derfor at sænke det røde flag vi rejste i december og foranlediget af tydelig fremgang for og mere visibilitet omkring den nye serviceforretning, hæver vi igen anbefalingen til KØB, og løfter kursmålet til 350 DKK fra 250 DKK". [image: 81897_72671612_10221344929558603_2373108776958951424_n.jpg]
  • Coronaviruset rammer Apple - Når ikke indtjeningsmål

    5
    0 Votes
    5 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    PRESS RELEASE February 17, 2020 Investor update on quarterly guidance Cupertino, California - February 17, 2020 - As the public health response to COVID-19 continues, our thoughts remain with the communities and individuals most deeply affected by the disease, and with those working around the clock to contain its spread and to treat the ill. Apple is more than doubling our previously announced donation to support this historic public health effort. Our quarterly guidance issued on January 28, 2020 reflected the best information available at the time as well as our best estimates about the pace of return to work following the end of the extended Chinese New Year holiday on February 10. Work is starting to resume around the country, but we are experiencing a slower return to normal conditions than we had anticipated. As a result, we do not expect to meet the revenue guidance we provided for the March quarter due to two main factors. The first is that worldwide iPhone supply will be temporarily constrained. While our iPhone manufacturing partner sites are located outside the Hubei province - and while all of these facilities have reopened - they are ramping up more slowly than we had anticipated. The health and well-being of every person who helps make these products possible is our paramount priority, and we are working in close consultation with our suppliers and public health experts as this ramp continues. These iPhone supply shortages will temporarily affect revenues worldwide. The second is that demand for our products within China has been affected. All of our stores in China and many of our partner stores have been closed. Additionally, stores that are open have been operating at reduced hours and with very low customer traffic. We are gradually reopening our retail stores and will continue to do so as steadily and safely as we can. Our corporate offices and contact centers in China are open, and our online stores have remained open throughout. Outside of China, customer demand across our product and service categories has been strong to date and in line with our expectations. The situation is evolving, and we will provide more information during our next earnings call in April. Apple is fundamentally strong, and this disruption to our business is only temporary. Our first priority - now and always - is the health and safety of our employees, supply chain partners, customers and the communities in which we operate. Our profound gratitude is with those on the front lines of confronting this public health emergency. This update contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about the Company's expected future financial results. These statements involve risks and uncertainties, and actual results may differ. Risks and uncertainties include without limitation: the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services and technological innovations on a timely basis; the effect that shifts in the mix of products and services and in the geographic, currency or channel mix, component cost increases, increases in the cost of acquiring and delivering content for the Company's services, price competition, or the introduction of new products or services, including new products or services with higher cost structures, could have on the Company's gross margin; the dependency of the Company on the performance of distributors of the Company's products, including cellular network carriers and other resellers; the risk of write-downs on the value of inventory and other assets and purchase commitment cancellation risk; the continued availability on acceptable terms, or at all, of certain components, services and new technologies essential to the Company's business, including components and technologies that may only be available from single or limited sources; the dependency of the Company on manufacturing and logistics services provided by third parties, many of which are located outside of the US and which may affect the quality, quantity or cost of products manufactured or services rendered to the Company; the effect of product and services design and manufacturing defects on the Company's financial performance and reputation; the dependency of the Company on third-party intellectual property and digital content, which may not be available to the Company on commercially reasonable terms or at all; the dependency of the Company on support from third-party software developers to develop and maintain software applications and services for the Company's products; the impact of unfavorable legal proceedings, such as a potential finding that the Company has infringed on the intellectual property rights of others; the impact of complex and changing laws and regulations worldwide, which expose the Company to potential liabilities, increased costs and other adverse effects on the Company's business; the ability of the Company to manage risks associated with the Company's retail stores; the ability of the Company to manage risks associated with the Company's investments in new business strategies and acquisitions; the impact on the Company's business and reputation from information technology system failures, network disruptions or losses or unauthorized access to, or release of, confidential information; the ability of the Company to comply with laws and regulations regarding data protection; the continued service and availability of key executives and employees; political events, international trade disputes, war, terrorism, natural disasters, public health issues, including the outbreak of COVID-19, and other business interruptions that could disrupt supply or delivery of, or demand for, the Company's products; financial risks, including risks relating to currency fluctuations, credit risks and fluctuations in the market value of the Company's investment portfolio; and changes in tax rates and exposure to additional tax liabilities. More information on these risks and other potential factors that could affect the Company's financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to further update its guidance for the second quarter ending March 28, 2020, or any other forward-looking statements or information, which speak as of their respective dates. Apple revolutionized personal technology with the introduction of the Macintosh in 1984. Today, Apple leads the world in innovation with iPhone, iPad, Mac, Apple Watch and Apple TV. Apple's four software platforms - iOS, macOS, watchOS and tvOS - provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud. Apple's more than 100,000 employees are dedicated to making the best products on earth, and to leaving the world better than we found it. Press Contact Kristin Huguet Quayle Apple [email protected] (408) 974-2414 https://www.apple.com/newsroom/2020/02/investor-update-on-quarterly-guidance/
  • Investordøden

    6
    0 Votes
    6 Indlæg
    0 Visninger
    C
    D.10-02-2020, købte jeg 12 fuldstændigt tilfældige aktier i C20-largecap-smallcap, 4 fra hver, status i dag, alle 12 er med overskud, i større eller mindre grad. Det er der vi befinder os i dag, alle vindere, ingen tabere, måske lidt fjollet, men jeg har efterhånden levet i 20 år af at være professionel investor, også lidt stolt af det jeg har opnået med en vis grad af økonomisk uafhængihed. Det indebærer selvsagt en stor daglig arbejdsindsats med analyser, undersøgelser af markedspsykologi, investortræf, udvikling af egne analyseværktøjer, etc etc. Tilbage til min egen lille undersøgelse, 12 tilfældige aktier, 12 vindere, jeg sidder tilbage med én ængstelse jeg ikke kan abstrahere fra, jeg har altid lært at man skulle have respekt for markedet, men mit indtryk er det stik modsatte.
  • Tangiamo Touch Tech - Nu har jag köpt och tagit position

    0
    0 Votes
    0 Indlæg
    0 Visninger
    A
    Hittat en svensk gamingaktie verksam inom touchskärm-teknologi och mjukvaror till casinobranschen. Idag kom ett pressmeddelande igen. Jag har haft aktien på spaning ett tag och köpte in mig idag. Det ser ut som att bolaget kan få ett väldigt fint 2020. Vilka andra äger också Tangiamo Touch? Här är en bra sammanfattning på Dagens Industri: https://borssnack.di.se/#/borssnack/2425201 Jag ska skriva mer om Tangiamo snart. Jobbar på en egen analys.
  • Sprint spread - merger arbitrage

    0
    0 Votes
    0 Indlæg
    0 Visninger
    tommycarstensenT
    Looks like SoftBank decided to take a small hit and thankfully common shareholders of Sprint were not impacted. It is astounding that the spread on the deal is still 7.64% or nearly 70% annualized if the deal closes by 3/31/2020. $S $TMUS https://twitter.com/AsifSuria/status/1230681840224100352?s=19
  • GENMAB: Helge Larsen: De gør det helt rigtige

    2
    0 Votes
    2 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Lyt med fra 9,15 inde i udsendelsen. https://www.euroinvestor.dk/nyheder/helge-larsen-de-goer-det-helt-rigtige. Lyt med 15 min. inde i udsendelsen.
  • Scientists: COVID-19 originated from bioweapon facility?

    16
    0 Votes
    16 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    "Many leading Chinese scientists are starting to speak out and say COVID-19 (coronavirus) originated at a government bioweapons research facility in Wuhan, rather than the widely-held belief that it emerged from the city's Huanan seafood markets". https://www.youtube.com/watch?v=ZC0gww2yznI&feature=youtu.be
  • En bedre faktor end udbytte-procent

    10
    0 Votes
    10 Indlæg
    0 Visninger
    M
    Så er der en ny engelsk video oppe. Her tager jeg fat på udbytteinvesteringer, hvor mange nye investorer hurtigt forelsker sig i det rene udbytte som en passiv indtægt. Dette kan for så vidt være ok, men der er en anden faktor, der historisk set har været lidt bedre at kigge på, nemlig den såkaldte "Shareholder yield" Se med her og lær om forskellen samt, hvordan de forskellige tilgange har performet siden 1927. https://www.youtube.com/watch?v=awpElMtVHPs
  • Simcorp ..

    8
    0 Votes
    8 Indlæg
    0 Visninger
    TheNoteT
    Simcorp fik fornylig lidt uventede tæv. På "dayli" er tendensen nu på vej op, men man bør have in mente at weekly faktisk IKKE er bundet ud endnu, så der består en risiko. På "dagssigt" ser det dog ud til at aktien er værd at samle op, og så kan vi jo HÅBE .. at bunden for denne gang er nået, hvilket i så fald kan give et pænt afkast. Alternativet er at ventetiden forlænges et stykke. Uanset om den korte gambling lykkes ser kursen også på mellemsigt fornuftig ud. Men tag en kigger !
  • Genmab årsregnskab

    4
    0 Votes
    4 Indlæg
    0 Visninger
    StockBullS
    Kursudviklingen kan man ikke klage over. Der dog ud som om vi rykker tættere på næste retracement. Er tungt lastst i Genmab men smider nok lidt sidst på ugen eller i.f.m næste dyk som jeg forventer vil blive start på 3 til 4 ugers retracement. Vi må se hvad dagen idag og imorgen byder på [image: 81844_Retracement.JPG]
  • Donation netop sendt

    1
    0 Votes
    1 Indlæg
    0 Visninger
    H
    Tak til Helge for at holde teknikken kørende
  • Afsnit 2 af Investeringspodcasten med Hansen og Larsen

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    I afsnit 2 af #Investeringspodcasten med Hansen og Larsen kan du høre om aktuelle selskaber, deres kursudvikling og fremtidsudsigter. Snakken går på blandt andet Scatec Solar, Zealand Pharna, Norwegian, Teva, Photocure og kursbevægelserne inden for tankaktier. https://www.youtube.com/watch?v=3sTQo3CBTHg&feature=youtu.be
  • zealand, kort profittagning ?

    3
    0 Votes
    3 Indlæg
    0 Visninger
    TheNoteT
    Zealand viser nu lidt tegn på træthed. De korte bør måske overveje et genkøb på et andet niveau ? Men dagen er selvfølgelig ikke slut endnu og det sker jævnligt at toppen testes over 2 gange. Her lige et "closeup" af støtteområder i mit tidligere fremviste "POP" chart, såfremt de "store" ikke går ind og samler op sådan lige med det første. For de lange er mit chart naturligvis inderligt ligegyldigt. Men .. chart: https://invst.ly/pw193
  • GENMAB - Frank Hoerning Andersens om regnskabet

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Frank Hoerning Andersen 1st Investments ' Client Advisory ' Valuation ' Financial Analysis ' Communication ' Equity Research ' Healthcare Specialist: "Genmab is beefing up on R&D in 2020 primarily driven by investments in epcoritamab (DuoBody-CD3x-CD20) and DuoBody-PD-L1x4-1BB. Therefore earnings outlook for 2020 felt short of market expectations. I believe this is the right move as epcoritamab has a great potential in hematological malignancies. Early data for treatment of lymphoma presented at ASH 2019 indicated a strong efficacy and safety profile. With respect to Darzalex Genmab guides for sales of USD 3.9-4.2bn in 2020 slightly below market expectations. This should not raise concerns as Darzalex sales in 2020 should be propelled by larger impact from early lines of treatment, more patients getting treated with Darzalex and are living longer, and the likely approval of the subcutaneous formulation due in Q2'20". Kilde: Linkedin [image: 81875_77331538_10221940638530955_4467985749962129408_o.jpg]
  • Dansk-amerikansk startup vil kurere Alzheimers med "usynligt

    1
    0 Votes
    1 Indlæg
    0 Visninger
    J
    https://www.electronic-supply.dk/article/view/669475/danskamerikansk_startup_vil_kurere_alzheimers_med_usynligt_stroboskoplys
  • Udbytteguide

    2
    0 Votes
    2 Indlæg
    0 Visninger
    MatchM
    I 2019 havde Nordnet en udmærket udbytteguide for danske aktieselskabers generalforsamlingsdatoer samt udbyttebetaling. Det har de også i 2020, men den ser ikke ud til at blive opdateret. Findes der en god oversigt med tilsvarende oplysninger andetsteds på nettet?
  • FINGEPRINT CARDS: REVENUE & PROFIT DEVELOPMENT Overvåg

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Kilde: Nordic Stock. Klik på billedet for at gøre det tydligere. [image: 81828_Skaermbillede_2020_02_18_kl._17.23.07.jpg]
  • FINGEPRINT CARDS: REVENUE & PROFIT DEVELOPMENT

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Sorry. Forkert billede. Det kunne bruges i 2014. [image: 81827_12191781_10156282228270171_5158688533999539979_n.jpg]
  • Spændende pennyshares i US

    2
    0 Votes
    2 Indlæg
    0 Visninger
    M
    Hej med jer, Jeg har siddet og screenet US markedet for små og spændende pennyshares via FINVIZ. Jeg er specielt gået efter dem, hvor jeg synes, at teknikken er ved at indikere en bund efter at de respektive aktier er hamret helt i bund. Samtidig har der været store insiderkøb direkte i markedet i de aktier, jeg har fundet, og så er der blevet købt nogle frimærker i dem, netop pga. risikoen da vi er i de små aktier. NBEV KZR RIBT PGEN (tidligere XON) DRRX AMRS og så også SRNE, som oplevede bud på aktien fra en Private Equity fond på op til kurs 7USD (ligger nu i 2,7), men som blev afvist af bestyrelsen, da man mener, at tilbuddet ikke afspejler de reelle værdier i selvskabet. Den er også faldet pænt nu. Tænker at disse aktier kunne være steget betragteligt, hvis de ligger i mindst 12-24 mdr.. i hvert fald altid interesant når insiderne går massivt ind på de meget lave niveauer.
  • Gambling

    81
    0 Votes
    81 Indlæg
    0 Visninger
    M
    Jeg har for nogen tid siden lovet en liste over aktier inden for gambling og gaming. Her er Gamling listen. Jeg vil gennemgå de enkelte aktier henadvejen. Dele links og tanker omkring branchen. Jeg håber at kunne starte debat om branchen. Jeg følger: Kindred group Betsson Leovegas Cherryforetagenet Catena Media Netentertainment Jeg ligger tungt og langt i dem alle. Lige nu er jeg overvægtet i Leovegas, Cherry og Cantena Media. Gambling vokser ca 8 % pr. år. Det er en moden branche under konsolidering. Man skal kun gå efter de store spillere. De store handler historisk til PE på ca 20. Betaler typpisk 4-5% i udbytte og vokser typisk 10-20% om året. Gambling er sportsbetting og onlinecasino. Onlinecasino er de klassiske casinospil og slotmaaskiner.